New data suggest that breast cancer patients with HER2- and basal-molecular subtypes are more likely to respond to neoadjuvant chemotherapy than patients with luminal-type molecular subtype characteristics. The findings were released at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS)...
More...